Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ocrelizumab in Autoimmune Encephalitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 or greater~2. Able to obtain informed consent from patient or appropriate designee~3. Possible autoimmune encephalitis as defined by Table 1:~   1. Reasonable exclusion of alternative causes~  2. Subacute onset (\< 3 months) of memory deficits, altered consciousness, and/or psychiatric symptoms~  3. One or more of the following:~      * CSF (cerebrospinal fluid) pleocytosis (\>5 cells/µl corrected, if necessary, for traumatic lumbar puncture)~     * EEG (electroencephalogram) with epileptiform or focal slow wave abnormalities involving temporal lobes~     * Brain abnormalities on T2/FLAIR MRI restricted to the mesial temporal (limbic) lobes~     * Associated dyskinesias (faciobrachial dystonic movements or orofacial dyskinesias)~4. Completed initial treatment with iv steroids (at least 3000mg solumedrol) and plasma exchange (at least 3 exchanges) within the past 8 weeks~5. Presence of one (or more) of the following autoantibodies in serum or CSF~   * NMDA receptor~  * LGI1~  * CASPR2~  * DPPX~Exclusion Criteria:~1. Prior immunosuppression treatment in past year (other than steroids, intravenous immunoglobulin and plasma exchange)~2. Active malignancy requiring chemotherapy~3. Pregnancy~4. Evidence of active hepatitis or tuberculosis infection~5. Medical condition that (in investigators opinion) precludes the use of ocrelizumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: ACTIVE_COMPARATOR): Ocrelizumab will be administered 3 times over a 1 year study period. Subjects will receive a dose of 300 mg at week 0 (baseline) and again at week 2. The final dose of 600 mg will be administered at week 24.
- Treatment Placebo Arm (Type: PLACEBO_COMPARATOR): Saline will be used as the matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).